BriaCell Therapeutics Corp. filed a Form S-1 registration statement for an initial public offering on 2025-04-22. It has amended it 3 times. It filed its final prospectus on 2026-01-14, at a public offering price of $5.59 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
The Warrants have been approved for listing on Nasdaq under the symbol “BCTXL”.From the 424B4 filed 2026-01-14
Shares offered
4,677,202 shares, based on an assumed public offering price of $8.95 per share (which is the last reported sale price of our common shares on Nasdaq on December 19, 2025) and assumes no sale of Pre-funded Units, which, if sold, would reduce the number of common shares that we are offering on a one-for-one basis.From the S-1 filed 2025-12-23
Offering price
After giving effect to the Offering and our sale of the Common Units in the Offering at the public offering price of $5.59 per Common Unit (and $5.589 per Pre-funded Units), and after deducting the placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of October 31, 2025, would have been $36.8 million, or $5.94 per common share.From the 424B4 filed 2026-01-14
Use of proceeds
We currently intend to use the net proceeds from this Offering to fund working capital requirements, general corporate purposes and the advancement of business objectives.From the 424B4 filed 2026-01-14
Net loss or income
On July 3, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq indicating that, based upon the Company’s market value of listed securities (“MVLS”) for the 33 consecutive business days from May 15, 2024, to July 2, 2024, the Company did not meet the minimum MVLS of $35,000,000, $2.5 million shareholders’ equity or $500,000 of net income from continuing operations requirements for The Nasdaq Capital Market set forth in Listing Rules 5550(b)(2), 5550(b)(1), or 5550(b)(3) (the “Rules”) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(2).From the S-1 filed 2025-12-23
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-04-22 | Registration statement filed | S-1 |
| 2025-04-23 | Registration statement amended | S-1/A |
| 2025-04-28 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-04-28 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-07-08 | Registration statement filed | S-1 |
| 2025-07-09 | Registration statement amended | S-1/A |
| 2025-07-10 | Registration statement amended | S-1/A |
| 2025-07-16 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-12-23 | Registration statement filed | S-1 |
| 2026-01-14 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for BriaCell Therapeutics Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.